药康生物
(688046)
| 流通市值：150.54亿 | | | 总市值：150.54亿 |
| 流通股本：4.10亿 | | | 总股本：4.10亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 459,550,008.7 | 208,076,700 | 793,389,024.92 | 575,576,818.48 |
| 营业总成本 | 337,486,941.16 | 156,814,985.14 | 624,226,092.52 | 446,747,545.25 |
| 其他经营收益 | | | | |
| 营业利润 | 120,809,231.67 | 53,555,759.19 | 165,118,101.96 | 120,290,164.38 |
| 利润总额 | 124,269,473.18 | 53,555,015.6 | 164,922,208.16 | 120,160,805.79 |
| 净利润 | 110,814,393.33 | 47,103,795.92 | 142,636,806.31 | 109,900,074.6 |
| 每股收益 | | | | |
| 其他综合收益 | 982,764.48 | 1,472,862.18 | -1,566,598.08 | -471,982.53 |
| 综合收益总额 | 111,797,157.81 | 48,576,658.1 | 141,070,208.23 | 109,428,092.06 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,701,850,786.24 | 1,711,353,086.17 | 1,751,473,680.52 | 1,791,318,747.03 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,137,228,374.86 | 1,156,685,043.76 | 1,113,593,130.95 | 1,038,737,191.68 |
| 资产总计 | 2,839,079,161.1 | 2,868,038,129.93 | 2,865,066,811.47 | 2,830,055,938.71 |
| 流动负债: | | | | |
| 流动负债合计 | 469,133,639.54 | 477,623,308.75 | 527,144,152.75 | 542,562,949.01 |
| 非流动负债: | | | | |
| 非流动负债合计 | 103,562,621.31 | 111,530,123.51 | 110,725,505.15 | 86,446,661.16 |
| 负债合计 | 572,696,260.85 | 589,153,432.26 | 637,869,657.9 | 629,009,610.17 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,266,382,900.25 | 2,278,884,697.67 | 2,227,197,153.57 | 2,201,046,328.54 |
| 股东权益合计 | 2,266,382,900.25 | 2,278,884,697.67 | 2,227,197,153.57 | 2,201,046,328.54 |
| 负债和股东权益合计 | 2,839,079,161.1 | 2,868,038,129.93 | 2,865,066,811.47 | 2,830,055,938.71 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 439,128,873.91 | 176,656,119.21 | 845,227,504.87 | 532,286,911.78 |
| 经营活动现金流出小计 | 351,093,892.06 | 180,746,032.95 | 618,200,507.82 | 445,112,587.11 |
| 经营活动产生的现金流量净额 | 88,034,981.85 | -4,089,913.74 | 227,026,997.05 | 87,174,324.67 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,582,819,556.99 | 939,952,273.22 | 2,566,710,815.81 | 1,745,964,074.19 |
| 投资活动现金流出小计 | 1,686,785,247.89 | 969,692,800.55 | 3,033,291,033.51 | 2,339,423,327.69 |
| 投资活动产生的现金流量净额 | -103,965,690.9 | -29,740,527.33 | -466,580,217.7 | -593,459,253.5 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 100,911,178.67 | 29,210,000 | 313,015,082.88 | 266,418,263.99 |
| 筹资活动现金流出小计 | 241,120,918.65 | 62,456,549.44 | 286,121,363.21 | 157,111,764.73 |
| 筹资活动产生的现金流量净额 | -140,209,739.98 | -33,246,549.44 | 26,893,719.67 | 109,306,499.26 |
| 汇率变动对现金及现金等价物的影响 | -7,879,409.4 | -4,357,164.26 | -2,614,681.67 | 54,614.88 |
| 现金及现金等价物净增加额 | -164,019,858.43 | -71,434,154.77 | -215,274,182.65 | -396,923,814.7 |
| 期末现金及现金等价物余额 | 321,921,401.65 | 414,478,083.73 | 485,941,260.08 | 304,291,628.03 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -164,019,858.43 | - | -215,274,182.65 | - |
最新报告期：2026-07-22| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,袁中平,陈睿恬 | 0.51 | 0.62 | 0.75 | 2026-07-22 |
| 浙商证券 | 胡隽扬 | 0.47 | 0.61 | 0.79 | 2026-06-16 |